We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
-5.66%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$108M
AUM Growth
-$175M
Cap. Flow
-$179M
Cap. Flow %
-165.02%
Top 10 Hldgs %
92.43%
Holding
31
New
6
Increased
13
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
SBBP
Strongbridge Biopharma plc.
SBBP
+$4.59M
2
MTEM
Molecular Templates, Inc.
MTEM
+$2.79M
3
SCYX icon
SCYNEXIS
SCYX
+$2.02M
4
KALA icon
KALA BIO
KALA
+$640K
5
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$489K

Top Sells

Rank Stock Value
1
LITS
Lite Strategy Inc
LITS
+$2.95M
2
ONCT
Oncternal Therapeutics, Inc. Common Stock
ONCT
+$763K
3
BBDC icon
Barings BDC
BBDC
+$302K
4
GARS
Garrison Capital Inc.
GARS
+$50.5K
5
MRKR icon
Marker Therapeutics
MRKR
+$26.9K

Sector Composition

Rank Sector Weight
1 Healthcare 60.25%
2 Financials 9.15%
3 Real Estate 1.4%
4 Utilities 0.96%
5 Industrials 0.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIRX
26
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$222K 0.21%
3,178
+1,786
+128% +$136K
MRNS
27
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$202K 0.19%
5,045
+1,769
+54% +$50.3K
CACC icon
28
Credit Acceptance
CACC
$6.69B
$201K 0.19%
+459
New +$193K
SRRA
29
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$190K 0.18%
2,797
+1,954
+232% +$177K
BBDC icon
30
Barings BDC
BBDC
$890M
– –
-26,286
Closed -$302K
ONCT
31
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
– –
-356
Closed -$763K
1
2

Similar funds

PCM
Pathway Capital Management Irvine, California $4.3M AUM 62.8% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
RA
Ritter Alpha New York $4.78M AUM
CGA
Compound Global Advisors Mercer Island, Washington $3.22M AUM 30.08% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ABA
American Beacon Advisors Irving, Texas $5.08M AUM 20.11% 1-Year Est. Return
UOMF
University of Maryland Foundation Adelphi, Maryland $5.1M AUM 10.69% 1-Year Est. Return

Caxton Corporation's Q3 2018 Portfolio in Review

As of Q3 2018, Caxton Corporation held 31 positions worth $108M, down 62% from $283M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Caxton Corporation withdrew a net $179M in Q3 2018, closing 2 positions and reducing 5 holdings. Its most notable exit was Oncternal Therapeutics, Inc. Common Stock, an estimated $763K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 22% a quarter earlier, followed by Financials and Real Estate.

Against the trend, Caxton Corporation opened a new position in KALA BIO worth $506K.

  • Caxton Corporation's largest Q3 2018 buy was KALA BIO: 21 shares worth $506K.
  • Caxton Corporation added most to Strongbridge Biopharma plc. in Q3 2018, an estimated $4.59M increase.
  • Caxton Corporation's biggest Q3 2018 reduction was Lite Strategy Inc, cutting an estimated $2.95M.
  • Caxton Corporation fully exited Oncternal Therapeutics, Inc. Common Stock in Q3 2018, selling an estimated $763K.
  • Caxton Corporation's ten largest holdings make up 92% of its $108M portfolio in Q3 2018.
  • Caxton Corporation opened 6 new positions and closed 2 in Q3 2018.
  • Caxton Corporation's portfolio value fell 62% quarter-over-quarter to $108M.

Based on Caxton Corporation's 13F filing for Q3 2018, filed 14 Nov 2018.